First in human trial of new drug raises hopes

<p>A new targeted drug, studied by researchers at <a href="https://cancer.osu.edu/">The Ohio State University Comprehensive Cancer Center &ndash; Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC &ndash; James)</a>, may&nbsp;offer&nbsp;a new treatment option for patients with blood cancers, including chronic lymphocytic leukemia and Non-Hodgkin lymphoma&nbsp;whose disease has stopped responding to standard treatments.</p>

Related Keywords

United States ,Columbus ,Ohio ,University Of Cincinnati ,Ohio State University ,Lindsey Granlund ,Mohammed Farooqui ,Brian Schwartz ,Sudharshan Eathiraj ,Jennifer Woyach ,Arthurg James ,Elizabeth Muhowski ,Ian Flinn ,Deborah Stephens ,Johnc Byrd ,Wayne Wang ,Sean Reiff ,Lyndsey Szuszkiewicz ,Razi Ghori ,Feng Chai ,Method Of Research ,Merck Co ,Leukemia Research Program ,Sarah Cannon Research Institute ,Huntsman Cancer Institute ,Richardj Solove Research Institute ,Ohio State University Comprehensive Cancer Center ,University Of Cincinnati College Medicine ,Arqule Inc ,Ohio State University Wexner Medical Center ,Cancer Hospital ,Research Institute ,Seema Bhat ,Ronald Savage ,Cincinnati College ,Human Study ,Refractory Chronic Lymphocytic Leukemia ,B Cell Non Hodgkin ,